Sarepta Therapeutics Provides Update on ELEVIDYS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Strong earthquake rocks north-central Venezuela, capital Caracas
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
April 4, 2025 12:28 PM EDTBarclays analyst Gena Wang reiterated an Overweight rating and $209.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "Key takeaways. Following the EU's temporary halt of ongoing Elevidys studies due to recent safety update, SRPT provided another update on an independent data... More
